BCM
CHRS icon

Bourgeon Capital Management’s Coherus Oncology CHRS Stock Holding History

Bourgeon Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-13,400
Closed -$226K – 94
2016
Q2 		$226K Buy
+13,400
New +$252K 0.15% 77
2015
Q4 		– Sell
-17,500
Closed -$351K – 92
2015
Q3 		$351K Buy
17,500
+7,500
+75% +$228K 0.25% 72
2015
Q2 		$289K Buy
+10,000
New +$253K 0.18% 90

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bourgeon Capital Management's CHRS Position: Q3 2016 in Review

Bourgeon Capital Management sold out of Coherus Oncology (CHRS) in Q3 2016, closing a stake of 13,400 shares — an estimated $226K sold.

Bourgeon Capital Management first reported a position in CHRS in Q2 2015 and held it in 3 quarters. The position peaked at $351K in Q3 2015. 117 funds tracked by Wall St. Rank hold CHRS as of Q3 2016.

  • Bourgeon Capital Management reported no remaining Coherus Oncology position as of Q3 2016 after selling out during the quarter.
  • Bourgeon Capital Management sold 13,400 Coherus Oncology shares in Q3 2016, an estimated $226K.
  • Bourgeon Capital Management first reported a position in Coherus Oncology in Q2 2015 and held it in 3 quarters.
  • Bourgeon Capital Management's Coherus Oncology position peaked at $351K in Q3 2015.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2016.

Based on Bourgeon Capital Management's 13F filing for Q3 2016, filed 26 Oct 2016.